A Phase 3 interventional study of Nilotinib in Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), sponsored by Novartis Pharmaceuticals. Completed at 208 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 2nd largest by enrollment, is one of 11 that started in 2013, is one of 15 in phase 3, and was the 39th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 26 more countries
Ages 7–100
Medical College of Wisconsin · Sites in United States
Ages 18+
By country, each count listing its studies:
nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 32 · Phase 3 16 · Phase 4 12
First in 2001; this study’s year is marked. 11 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 620 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 55 across the 66 interventional studies. Of the 54 that completed or were terminated, 29 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 66 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 3rd largest by enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2013, is one of 19 in phase 3, and was the 50th registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
This study aimed to assess the optimal duration of nilotinib 300 mg twice daily (BID) consolidation treatment in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), in order that patients remained in treatment-free remission (≥MR4.0) without molecular relapse 12 months after starting the Treatment-Free Remission (TFR) phase.
This was a prospective, randomized, open-label, multicenter Phase III study. The study design was made up of 3 phases:
Subjects were enrolled into the study and were treated with nilotinib 300mg twice daily (BID) for 24 months, during the induction (12 months) and consolidation (12 months) phases. At the end of the first 24 months of treatment, participants achieving a sustained molecular response (defined as ≥ MR4.0, in 4 out of 5 real-time quantitative polymerase chain reaction (RQ-PCR) assessments, including the last assessment, in the last 12 months) were randomized on a 1:1 basis to either:
Participants not achieving a sustained molecular response at 24 months from treatment start were not eligible for randomization and were treated at the discretion of the investigator according to standard practice. Information on survival, stem cell transplantation, and status of the patient's disease was collected until death or until 5 years from study entry, whichever came first. Additionally, for Nilotinib 36-month treatment arm, participants who did not achieve a sustained molecular response at 36 months from treatment start, discontinued from the study and were treated according to standard practice and followed up until death or until 5 years from study entry, whichever came first.
Participants relapsing during the TFR phase entered the nilotinib re-treatment phase of the study, and were re-treated with the same dose of nilotinib as they were on before the TFR phase. These patients remained on study until the completion of the 5-year study period unless prematurely withdrawn and discontinued from the study for any reason specified in the Protocol.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other inclusion/exclusion criteria might apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were treated with nilotinib 300mg BID for 24 months and, thereafter, entered the 36-month TFR phase
Drug: Nilotinib
Participants were treated with nilotinib 300mg BID for 36 months and, thereafter, entered the 24-month TFR phase
Drug: Nilotinib
Participants were treated with nolotinib 300mg BID for 24 months, but did not achieve a sustained molecular response after 24 months of treatment.
Drug: Nilotinib
Participants received a daily oral nilotinib dose of 300 mg BID, given as two 150 mg capsules BID.
Also known as: AMN107
Percentage of Participants Who Remained in Treatment Free Remission (TFR) Without Molecular Relapse 12 Months After Entering the TFR Phase
Number of participants who remained in TFR (≥molecular response (MR) 4.0) without molecular relapse 12 months after entering the TFR phase (without re-starting nilotinib therapy) divided by the number of participants who entered the TFR phase and multiplied by 100. Molecular relapse during TFR is defined as the loss of major molecular response (MMR), or the confirmed loss of MR4.0 (defined by 3 consecutive tests less than MR4.0 assessed at 3 consecutive visits during TFR phase). Participants dropping out early from the study during the TFR phase were considered as unsuccessful TFR. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL. MR4.0 is defined as either detectable disease≤0.01% BCR-ABL or undetectable disease in cDNA with≥10,000 ABL transcripts
Time frame: 12 months after entering the TFR phase, which is after 36 months from study treatment start for Nilotinib 24-month treatment arm and after 48 months from study treatment start for Nilotinib 36-month treatment arm
Cumulative Incidence of MMR During the Pre-randomization Induction/Consolidation Phase Among Participants Without That Response at Study Entry
Number of participants who were in MMR during pre-randomization induction/consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.
Time frame: From baseline up to 24 months after study treatment start
Cumulative Incidence of MMR During the Post-randomization Consolidation Phase Among Participants Without That Response at Study Entry
Number of participants who were in MMR during post-randomization consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.
Time frame: From randomization (month 24 after study treatment start) up to 36 months after study treatment start
Cumulative Incidence of MR4.0 During the Pre-randomization Induction/Consolidation Phase Among Participants Without That Response at Study Entry
Number of participants who were in MR4.0 during the pre-randomization induction/consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
Time frame: From baseline up to 24 months after study treatment start
Cumulative Incidence of MR4.0 During the Post-randomization Consolidation Phase Among Participants Without That Response at Study Entry
Number of participants who were in MR4.0 during the post-randomization consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
Time frame: From randomization (month 24 after study treatment start) up to 36 months after study treatment start
Cumulative Incidence of MR4.5 During the Pre-randomization Induction/Consolidation Phase Among Participants Without That Response at Study Entry
Number of participants who were in MR4.5 during the pre-randomization induction/consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
Time frame: From baseline up to 24 months after study treatment start
Cumulative Incidence of MR4.5 During the Post-randomization Consolidation Phase Among Participants Without That Response at Study Entry
Number of participants who were in MR4.5 during the post-randomization consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
Time frame: From randomization (month 24 after study treatment start) up to 36 months after study treatment start
Cumulative Incidence of MMR During the Pre-randomization Induction/Consolidation Phase
Number of participants who were in MMR during the pre-randomization induction/consolidation phase divided by the number of enrolled participants and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.
Time frame: From baseline up to 24 months after study treatment start
Cumulative Incidence of MMR During the Post-randomization Consolidation Phase
Number of participants who were in MMR during the post-randomization consolidation phase divided by the number of enrolled participants and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.
Time frame: From randomization (month 24 after study treatment start) up to 36 months after study treatment start
Cumulative Incidence of MR4.0 During the Pre-randomization Induction/Consolidation Phase
Number of participants who were in MR4.0 during the pre-randomization induction/consolidation phase divided by the number of enrolled participants and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
Time frame: From baseline up to 24 months after study treatment start
Cumulative Incidence of MR4.0 During the Post-randomization Consolidation Phase
Number of participants who were in MR4.0 during the post-randomization consolidation phase divided by the number of enrolled participants and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
Time frame: From randomization (month 24 after study treatment start) up to 36 months after study treatment start
Cumulative Incidence of MR4.5 During the Pre-randomization Induction/Consolidation Phase
Number of participants who were in MR4.5 during the pre-randomization induction/consolidation phase divided by the number of enrolled participants and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
Time frame: From baseline up to 24 months after study treatment start
Cumulative Incidence of MR4.5 During the Post-randomization Consolidation Phase
Number of participants who were in MR4.5 during the post-randomization consolidation phase divided by the number of enrolled participants and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
Time frame: From randomization (month 24 after study treatment start) up to 36 months after study treatment start
Percentage of Participants Who Were in MMR During TFR Phase
Number of participants who were in MMR at selected timepoints divided by the number of participants in the TFR phase and multiplied by 100. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.
Time frame: From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
Percentage of Participants Who Were in MR4.0 During the TFR Phase
Number of participants who were in MR4.0 at selected timepoints divided by the number of participants in the TFR phase and multiplied by 100. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
Time frame: From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotininb 36-months treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-months treatment arm
Percentage of Participants Who Were in MR4.5 During the TFR Phase
Number of participants who were in MR4.5 at selected timepoints divided by the number of participants in the TFR phase and multiplied by 100. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
Time frame: From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotininb 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
BCR-ABL Ratio (Expressed as a Percentage) During the Induction/Consolidation Phase
BCR-ABL transcript ratio by international scale (IS) (expressed as a percentage) during the induction/consolidation phase. Participants randomized to Nilotinib 36-month treatment arm had 12-month additional consolidation phase (post-randomization).
Time frame: From baseline up to 24 months after study treatment start for Nilotinib 24-month treatment arm and Not randomized participants; and up to 36 months after study treatment start for Nilotinib 36-month treatment arm.
BCR-ABL Ratio (Expressed as a Percentage) During the TFR Phase
BCR-ABL/control gene (ABL) transcript ratio by international scale (IS) (expressed as a percentage) during the TFR phase. BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase.
Time frame: From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
BCR-ABL Ratio (Expressed as a Percentage) During the Nilotinib Re-treatment Phase
BCR-ABL/control gene (ABL) transcript ratio by international scale (IS) (expressed as a percentage) during the nilotinib re-treatment phase. BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes.
Time frame: From Day 1 after entering the re-treatment phase up to 24 months after entering re-treatment phase for Nilotinib 36-month treatment arm and 36 months after entering the re-treatment phase for Nilotinib 24-month treatment arm
Progression-free Survival (PFS) During the TFR Phase of the Study.
PFS is defined as the time from the date of start of the nilotinib TFR phase to the date of acelerated phase/blast crisis (AP/BC) or death, whichever came first. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotini 24-month treatment arm had a maximum of 36 months of TFR phase. Patients not known to have recurred or died on or before the cut-off date for PFS analysis were censored at the date of their last assessment (cytogenetic, hematology or extramedullary) for patients who were on study, and at the date of last contact for patients who were in follow-up.
Time frame: From the start of the TFR phase to progression to AP/BC or death up to 24 months after entering TFR phase for Nilotininb 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
Treatment -Free Survival (TFS) During the TFR Phase of the Study
TFS is defined as the time from the start of the TFR phase to the date of the earliest of the following: loss of MMR, confirmed loss of MR4.0,re-start of nilotinib treatment, progression to AP/BC, or death from any cause. Patients not known to have had any of the events on or before the cut-off date were censored at the earlier of the date of their last assessment for patients who were still on study and the date of last contact for patients who were in follow-up. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1%BCR-ABL. MR4.0 is defined as either detectable disease ≤0.01%BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
Time frame: From the start of the TFR phase to the date of occurrence of treatment-free survival event, up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
Overall Survival (OS) Rate During the TFR Phase of the Study.
OS is defined as the time from start of the TFR phase to the time of death due to any cause. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotini 24-month treatment arm had a maximum of 36 months of TFR phase. For participants without any event on or before the cut-off date, survival time will be censored at the date of their last assessment for patients who are still on study, and at the date of last contact for patients who are in follow-up.
Time frame: From the start of the TFR phase to death due to any cause, assessed up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
| Milestone | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment | Not Randomized |
|---|---|---|---|
| Started | 120 | 119 | 381 |
| Participants who signed informed consent | 120 | 118 | 381 |
| Completed | 119 | 104 | 0 |
| Not completed | 1 | 15 | 381 |
| Withdrew: Unstable mr4.0 | 0 | 6 | 263 |
| Withdrew: Adverse event | 0 | 4 | 67 |
| Withdrew: Withdrawal by subject | 1 | 3 | 28 |
| Withdrew: Death | 0 | 1 | 3 |
| Withdrew: Abnormal laboratory value(s) | 0 | 0 | 3 |
| Withdrew: Protocol deviation | 0 | 0 | 3 |
| Withdrew: Pregnancy | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 |
| Withdrew: Abnormal test procedure result(s) | 0 | 0 | 1 |
| Withdrew: Administrative problems | 0 | 0 | 1 |
| Withdrew: New cancer (cml) therapy | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 3 |
| Withdrew: Patient non-compliance to treatment | 0 | 0 | 3 |
| Withdrew: Not randomized by mistake | 0 | 0 | 1 |
| Withdrew: Included by mistake | 0 | 0 | 1 |
| Milestone | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment | Not Randomized |
|---|---|---|---|
| Started | 119 | 104 | 0 |
| Completed | 37 | 36 | 0 |
| Not completed | 82 | 68 | 0 |
| Withdrew: Relapse (loss of mmr/confirmed loss of mr4.0) | 82 | 59 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Logistical problems | 0 | 2 | 0 |
| Withdrew: Protocol deviation | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 |
| Milestone | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment | Not Randomized |
|---|---|---|---|
| Started | 74 | 55 | 0 |
| Completed | 58 | 46 | 0 |
| Not completed | 16 | 9 | 0 |
| Withdrew: Adverse event | 8 | 4 | 0 |
| Withdrew: Death | 1 | 1 | 0 |
| Withdrew: Administrative problems | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 1 | 0 |
| Withdrew: Unstable mr | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
Number of participants who remained in TFR (≥molecular response (MR) 4.0) without molecular relapse 12 months after entering the TFR phase (without re-starting nilotinib therapy) divided by the number of participants who entered the TFR phase and multiplied by 100. Molecular relapse during TFR is defined as the loss of major molecular response (MMR), or the confirmed loss of MR4.0 (defined by 3 consecutive tests less than MR4.0 assessed at 3 consecutive visits during TFR phase). Participants dropping out early from the study during the TFR phase were considered as unsuccessful TFR. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL. MR4.0 is defined as either detectable disease≤0.01% BCR-ABL or undetectable disease in cDNA with≥10,000 ABL transcripts
| Percentage of participants | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment |
|---|---|---|
| Percentage of Participants Who Remained in Treatment Free Remission (TFR) Without Molecular Relapse 12 Months After Entering the TFR Phase | 31.9 (23.7 to 41.1) | 37.5 (28.2 to 47.5) |
Number of participants who were in MMR during pre-randomization induction/consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.
| Percentage of participants | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment | Not Randomized |
|---|---|---|---|
| Up to 3 months after study treatment start (pre-randomization) | 69.6 (47.1 to 86.8) | 37.5 (15.2 to 64.6) | 29.6 (20.8 to 39.7) |
| Up to 6 months after study treatment start (pre-randomization) | 100 (85.2 to 100.0) | 100.0 (79.4 to 100.0) | 64.3 (54.0 to 73.7) |
| Up to 9 months after study treatment start (pre-randomization) | 100 (85.2 to 100.0) | 100.0 (79.4 to 100.0) | 71.4 (61.4 to 80.1) |
| Up to 12 months after study treatment start (pre-randomization) | 100 (85.2 to 100.0) | 100.0 (79.4 to 100.0) | 77.6 (68.0 to 85.4) |
| Up to 15 months after study treatment start (pre-randomization) | 100 (85.2 to 100.0) | 100.0 (79.4 to 100.0) | 80.6 (71.4 to 87.9) |
| Up to 18 months after study treatment start (pre-randomization) | 100 (85.2 to 100.0) | 100.0 (79.4 to 100.0) | 82.7 (73.7 to 89.6) |
| Up to 21 months after study treatment start (pre-randomization) | 100 (85.2 to 100.0) | 100.0 (79.4 to 100.0) | 85.7 (77.2 to 92.0) |
| Up to 24 months after study treatment start (pre-randomization) | 100 (85.2 to 100.0) | 100.0 (79.4 to 100.0) | 86.7 (78.4 to 92.7) |
Number of participants who were in MMR during post-randomization consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.
| Percentage of participants | Nilotinib 36-month Treatment |
|---|---|
| Up to 27 months after study treatment start (post-randomization) | 100.0 (79.4 to 100.0) |
| Up to 30 months after study treatment start (post-randomization) | 100.0 (79.4 to 100.0) |
| Up to 33 months after study treatment start (post-randomization) | 100.0 (79.4 to 100.0) |
| Up to 36 months after study treatment start (post-randomization) | 100.0 (79.4 to 100.0) |
Number of participants who were in MR4.0 during the pre-randomization induction/consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
| Percentage of participants | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment | Not Randomized |
|---|---|---|---|
| Up to 3 months after study treatment start (pre-randomization) | 48.9 (38.3 to 59.6) | 38.3 (28.5 to 48.9) | 12.9 (9.6 to 16.8) |
| Up to 6 months after study treatment start (pre-randomization) | 85.9 (77.1 to 92.3) | 81.9 (72.6 to 89.1) | 26.6 (22.1 to 31.5) |
| Up to 9 months after study treatment start (pre-randomization) | 94.6 (87.8 to 98.2) | 92.6 (85.3 to 97.0) | 34.5 (29.5 to 39.6) |
| Up to 12 months after study treatment start (pre-randomization) | 96.7 (90.8 to 99.3) | 98.9 (94.2 to 100.0) | 39.2 (34.1 to 44.5) |
| Up to 15 months after study treatment start (pre-randomization) | 100.0 (96.1 to 100.0) | 98.9 (94.2 to 100.0) | 42.0 (36.8 to 47.3) |
| Up to 18 months after study treatment start (pre-randomization) | 100.0 (96.1 to 100.0) | 100.0 (96.2 to 100.0) | 45.1 (39.9 to 50.4) |
| Up to 21 months after study treatment start (pre-randomization) | 100.0 (96.1 to 100.0) | 100.0 (96.2 to 100.0) | 48.7 (43.4 to 54.1) |
| Up to 24 months after study treatment start (pre-randomization) | 100.0 (96.1 to 100.0) | 100.0 (96.2 to 100.0) | 52.1 (46.8 to 57.4) |
Number of participants who were in MR4.0 during the post-randomization consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
| Percentage of participants | Nilotinib 36-month Treatment |
|---|---|
| Up to 27 months after study treatment start (post-randomization) | 97.9 (92.5 to 99.7) |
| Up to 30 months after study treatment start (post-randomization) | 97.9 (92.5 to 99.7) |
| Up to 33 months after study treatment start (post-randomization) | 97.9 (92.5 to 99.7) |
| Up to 36 months after study treatment start (post-randomization) | 97.9 (92.5 to 99.7) |
Number of participants who were in MR4.5 during the pre-randomization induction/consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
| Percentage of participants | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment | Not Randomized |
|---|---|---|---|
| Up to 3 months after study treatment start (pre-randomization) | 21.1 (13.9 to 30.0) | 17.4 (10.8 to 25.9) | 4.0 (2.3 to 6.5) |
| Up to 6 months after study treatment start (pre-randomization) | 38.5 (29.4 to 48.3) | 38.5 (29.4 to 48.3) | 8.6 (5.9 to 11.9) |
| Up to 9 months after study treatment start (pre-randomization) | 57.8 (48.0 to 67.2) | 54.1 (44.3 to 63.7) | 10.7 (7.8 to 14.3) |
| Up to 12 months after study treatment start (pre-randomization) | 70.6 (61.2 to 79.0) | 65.1 (55.4 to 74.0) | 14.2 (10.8 to 18.1) |
| Up to 15 months after study treatment start (pre-randomization) | 79.8 (71.1 to 86.9) | 76.1 (67.0 to 83.8) | 15.2 (11.8 to 19.3) |
| Up to 18 months after study treatment start (pre-randomization) | 83.5 (75.2 to 89.9) | 80.7 (72.1 to 87.7) | 16.6 (13.0 to 20.7) |
| Up to 21 months after study treatment start (pre-randomization) | 85.3 (77.3 to 91.4) | 84.4 (76.2 to 90.6) | 18.4 (14.7 to 22.8) |
| Up to 24 months after study treatment start (pre-randomization) | 89.0 (81.6 to 94.2) | 89.0 (81.6 to 94.2) | 20.3 (16.4 to 24.8) |
Number of participants who were in MR4.5 during the post-randomization consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
| Percentage of participants | Nilotinib 36-month Treatment |
|---|---|
| Up to 27 months after study treatment start (post-randomization) | 70.6 (61.2 to 79.0) |
| Up to 30 months after study treatment start (post-randomization) | 76.1 (67.0 to 83.8) |
| Up to 33 months after study treatment start (post-randomization) | 84.4 (76.2 to 90.6) |
| Up to 36 months after study treatment start (post-randomization) | 87.2 (79.4 to 92.8) |
Number of participants who were in MMR during the pre-randomization induction/consolidation phase divided by the number of enrolled participants and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.
| Percentage of participants | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment | Not Randomized |
|---|---|---|---|
| Baseline | 80.8 (72.6 to 87.4) | 86.4 (78.9 to 92.1) | 74.3 (69.6 to 78.6) |
| Up to 3 months after study treatment start (pre-randomization) | 94.2 (88.4 to 97.6) | 91.5 (85.0 to 95.9) | 81.9 (77.7 to 85.6) |
| Up to 6 months after study treatment start (pre-randomization) | 100.0 (97.0 to 100.0) | 100.0 (96.9 to 100.0) | 90.8 (87.5 to 93.5) |
| Up to 9 months after study treatment start (pre-randomization) | 100.0 (97.0 to 100.0) | 100.0 (96.9 to 100.0) | 92.7 (89.6 to 95.1) |
| Up to 12 months after study treatment start (pre-randomization) | 100.0 (97.0 to 100.0) | 100.0 (96.9 to 100.0) | 94.2 (91.4 to 96.4) |
| Up to 15 months after study treatment start (pre-randomization) | 100.0 (97.0 to 100.0) | 100.0 (96.9 to 100.0) | 95.0 (92.3 to 97.0) |
| Up to 18 months after study treatment start (pre-randomization) | 100.0 (97.0 to 100.0) | 100.0 (96.9 to 100.0) | 95.5 (93.0 to 97.4) |
| Up to 21 months after study treatment start (pre-randomization) | 100.0 (97.0 to 100.0) | 100.0 (96.9 to 100.0) | 96.3 (93.9 to 98.0) |
| Up to 24 months after study treatment start (pre-randomization) | 100.0 (97.0 to 100.0) | 100.0 (96.9 to 100.0) | 96.6 (94.2 to 98.2) |
Number of participants who were in MMR during the post-randomization consolidation phase divided by the number of enrolled participants and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.
| Percentage of participants | Nilotinib 36-month Treatment |
|---|---|
| Up to 27 months after study treatment start (post-randomization) | 98.3 (94.0 to 99.8) |
| Up to 30 months after study treatment start (post-randomization) | 98.3 (94.0 to 99.8) |
| Up to 33 months after study treatment start (post-randomization) | 98.3 (94.0 to 99.8) |
| Up to 36 months after study treatment start (post-randomization) | 98.3 (94.0 to 99.8) |
Number of participants who were in MR4.0 during the pre-randomization induction/consolidation phase divided by the number of enrolled participants and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
| Percentage of participants | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment | Not Randomized |
|---|---|---|---|
| Baseline | 23.3 (16.1 to 31.9) | 20.3 (13.5 to 28.7) | 6.3 (4.1 to 9.2) |
| Up to 3 months after study treatment start (pre-randomization) | 60.8 (51.5 to 69.6) | 50.8 (41.5 to 60.2) | 18.4 (14.6 to 22.6) |
| Up to 6 months after study treatment start (pre-randomization) | 89.2 (82.2 to 94.1) | 85.6 (77.9 to 91.4) | 31.2 (26.6 to 36.2) |
| Up to 9 months after study treatment start (pre-randomization) | 95.8 (90.5 to 98.6) | 94.1 (88.2 to 97.6) | 38.6 (33.7 to 43.7) |
| Up to 12 months after study treatment start (pre-randomization) | 97.5 (92.9 to 99.5) | 99.2 (95.4 to 100.0) | 43.0 (38.0 to 48.2) |
| Up to 15 months after study treatment start (pre-randomization) | 100.0 (97.0 to 100.0) | 99.2 (95.4 to 100.0) | 45.7 (40.6 to 50.8) |
| Up to 18 months after study treatment start (pre-randomization) | 100.0 (97.0 to 100.0) | 100.0 (96.9 to 100.0) | 48.6 (43.4 to 53.7) |
| Up to 21 months after study treatment start (pre-randomization) | 100.0 (97.0 to 100.0) | 100.0 (96.9 to 100.0) | 52.0 (46.8 to 57.1) |
| Up to 24 months after study treatment start (pre-randomization) | 100.0 (97.0 to 100.0) | 100.0 (96.9 to 100.0) | 55.1 (50.0 to 60.2) |
Number of participants who were in MR4.0 during the post-randomization consolidation phase divided by the number of enrolled participants and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
| Percentage of participants | Nilotinib 36-month Treatment |
|---|---|
| Up to 27 months after study treatment start (post-randomization) | 98.3 (94.0 to 99.8) |
| Up to 30 months after study treatment start (post-randomization) | 98.3 (94.0 to 99.8) |
| Up to 33 months after study treatment start (post-randomization) | 98.3 (94.0 to 99.8) |
| Up to 36 months after study treatment start (post-randomization) | 98.3 (94.0 to 99.8) |
Number of participants who were in MR4.5 during the pre-randomization induction/consolidation phase divided by the number of enrolled participants and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
| Percentage of participants | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment | Not Randomized |
|---|---|---|---|
| Baseline | 9.2 (4.7 to 15.8) | 7.6 (3.6 to 14.0) | 1.8 (0.7 to 3.8) |
| Up to 3 months after study treatment start (pre-randomization) | 28.3 (20.5 to 37.3) | 23.7 (16.4 to 32.4) | 5.8 (3.7 to 8.6) |
| Up to 6 months after study treatment start (pre-randomization) | 44.2 (35.1 to 53.5) | 43.2 (34.1 to 52.7) | 10.2 (7.4 to 13.7) |
| Up to 9 months after study treatment start (pre-randomization) | 61.7 (52.4 to 70.4) | 57.6 (48.2 to 66.7) | 12.3 (9.2 to 16.1) |
| Up to 12 months after study treatment start (pre-randomization) | 73.3 (64.5 to 81.0) | 67.8 (58.6 to 76.1) | 15.7 (12.2 to 19.8) |
| Up to 15 months after study treatment start (pre-randomization) | 81.7 (73.6 to 88.1) | 78.0 (69.4 to 85.1) | 16.8 (13.2 to 20.9) |
| Up to 18 months after study treatment start (pre-randomization) | 85.0 (77.3 to 90.9) | 82.2 (74.1 to 88.6) | 18.1 (14.4 to 22.4) |
| Up to 21 months after study treatment start (pre-randomization) | 86.7 (79.3 to 92.2) | 85.6 (77.9 to 91.4) | 19.9 (16.1 to 24.3) |
| Up to 24 months after study treatment start (pre-randomization) | 90.0 (83.2 to 94.7) | 89.8 (82.9 to 94.6) | 21.8 (17.7 to 26.3) |
Number of participants who were in MR4.5 during the post-randomization consolidation phase divided by the number of enrolled participants and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
| Percentage of participants | Nilotinib 36-month Treatment |
|---|---|
| Up to 27 months after study treatment start (post-randomization) | 72.9 (63.9 to 80.7) |
| Up to 30 months after study treatment start (post-randomization) | 78.0 (69.4 to 85.1) |
| Up to 33 months after study treatment start (post-randomization) | 85.6 (77.9 to 91.4) |
| Up to 36 months after study treatment start (post-randomization) | 88.1 (80.9 to 93.4) |
Number of participants who were in MMR at selected timepoints divided by the number of participants in the TFR phase and multiplied by 100. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.
| Percentage of participants | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment |
|---|---|---|
| Month 1 after entering TFR phase | 97.5 (92.8 to 99.5) | 94.2 (87.9 to 97.9) |
| Month 2 after entering TFR phase | 84.9 (77.2 to 90.8) | 80.8 (71.9 to 87.8) |
| Month 3 after entering TFR phase | 62.2 (52.8 to 70.9) | 61.5 (51.5 to 70.9) |
| Month 4 after entering TFR phase | 51.3 (41.9 to 60.5) | 53.8 (43.8 to 63.7) |
| Month 5 after entering TFR phase | 45.4 (36.2 to 54.8) | 46.2 (36.3 to 56.2) |
| Month 6 after entering TFR phase | 42.9 (33.8 to 52.3) | 43.3 (33.6 to 53.4) |
| Month 8 after entering TFR phase | 40.3 (31.5 to 49.7) | 43.3 (33.6 to 53.4) |
| Month 10 after entering TFR phase | 38.7 (29.9 to 48.0) | 42.3 (32.7 to 52.4) |
| Month 12 after entering TFR phase | 36.1 (27.5 to 45.5) | 39.4 (30.0 to 49.5) |
| Month 15 after entering TFR phase | 35.3 (26.8 to 44.6) | 39.4 (30.0 to 49.5) |
| Month 18 after entering TFR phase | 35.3 (26.8 to 44.6) | 39.4 (30.0 to 49.5) |
| Month 21 after entering TFR phase | 34.5 (26.0 to 43.7) | 38.5 (29.1 to 48.5) |
| Month 24 after entering TFR phase | 31.9 (23.7 to 41.1) | 35.6 (26.4 to 45.6) |
| Month 27 after entering TFR phase | 31.9 (23.7 to 41.1) | — |
| Month 30 after entering TFR phase | 31.9 (23.7 to 41.1) | — |
| Month 33 after entering TFR phase | 30.3 (22.2 to 39.4) | — |
| Month 36 after entering TFR phase | 23.5 (16.2 to 32.2) | — |
Number of participants who were in MR4.0 at selected timepoints divided by the number of participants in the TFR phase and multiplied by 100. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
| Percentage of participants | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment Arm |
|---|---|---|
| Month 1 after entering TFR phase | 87.4 (80.1 to 92.8) | 83.7 (75.1 to 90.2) |
| Month 2 after entering TFR phase | 58.0 (48.6 to 67.0) | 56.7 (46.7 to 66.4) |
| Month 3 after entering TFR phase | 39.5 (30.7 to 48.9) | 42.3 (32.7 to 52.4) |
| Month 4 after entering TFR phase | 36.1 (27.5 to 45.5) | 42.3 (32.7 to 52.4) |
| Month 5 after entering TFR phase | 32.8 (24.5 to 42.0) | 41.3 (31.8 to 51.4) |
| Month 6 after entering TFR phase | 33.6 (25.2 to 42.9) | 38.5 (29.1 to 48.5) |
| Month 8 after entering TFR phase | 34.5 (26.0 to 43.7) | 40.4 (30.9 to 50.5) |
| Month 10 after entering TFR phase | 35.3 (26.8 to 44.6) | 38.5 (29.1 to 48.5) |
| Month 12 after entering TFR phase | 31.9 (23.7 to 41.1) | 37.5 (28.2 to 47.5) |
| Month 15 after entering TFR phase | 34.5 (26.0 to 43.7) | 34.6 (25.6 to 44.6) |
| Month 18 after entering TFR phase | 33.6 (25.2 to 42.9) | 38.5 (29.1 to 48.5) |
| Month 21 after entering TFR phase | 30.3 (22.2 to 39.4) | 32.7 (23.8 to 42.6) |
| Month 24 after entering TFR phase | 29.4 (21.4 to 38.5) | 30.8 (22.1 to 40.6) |
| Month 27 after entering TFR phase | 31.1 (22.9 to 40.2) | — |
| Month 30 after entering TFR phase | 30.3 (22.2 to 39.4) | — |
| Month 33 after entering TFR phase | 27.7 (19.9 to 36.7) | — |
| Month 36 after entering TFR phase | 26.1 (18.4 to 34.9) | — |
Number of participants who were in MR4.5 at selected timepoints divided by the number of participants in the TFR phase and multiplied by 100. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
| Percentage of participants | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment Arm |
|---|---|---|
| Month 3 after entering TFR phase | 21.8 (14.8 to 30.4) | 26.9 (18.7 to 36.5) |
| Month 6 after entering TFR phase | 17.6 (11.3 to 25.7) | 28.8 (20.4 to 38.6) |
| Month 12 after entering TFR phase | 20.2 (13.4 to 28.5) | 26.9 (18.7 to 36.5) |
| Month 15 after entering TFR phase | 18.5 (12.0 to 26.6) | 23.1 (15.4 to 32.4) |
| Month 18 after entering TFR phase | 25.2 (17.7 to 34.0) | 26.9 (18.7 to 36.5) |
| Month 21 after entering TFR phase | 22.7 (15.5 to 31.3) | 22.1 (14.6 to 31.3) |
| Month 24 after entering TFR phase | 24.4 (17.0 to 33.1) | 20.2 (13.0 to 29.2) |
| Month 27 after entering TFR phase | 21.8 (14.8 to 30.4) | — |
| Month 30 after entering TFR phase | 22.7 (15.5 to 31.3) | — |
| Month 33 after entering TFR phase | 19.3 (12.7 to 27.6) | — |
| Month 36 after entering TFR phase | 16.8 (10.6 to 24.8) | — |
BCR-ABL transcript ratio by international scale (IS) (expressed as a percentage) during the induction/consolidation phase. Participants randomized to Nilotinib 36-month treatment arm had 12-month additional consolidation phase (post-randomization).
| Percentage | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment Arm | Not Randomized |
|---|---|---|---|
| Baseline | 0.1367 ± 0.55144 | 0.0633 ± 0.12790 | 0.5509 ± 3.94256 |
| Month 3 after study treatment start (pre-randomization) | 0.0106 ± 0.02660 | 0.0086 ± 0.01155 | 0.0728 ± 0.22537 |
| Month 6 after study treatment start (pre-randomization) | 0.0052 ± 0.00631 | 0.0124 ± 0.05508 | 0.0530 ± 0.09587 |
| Month 9 after study treatment start (pre-randomization) | 0.0049 ± 0.00809 | 0.0046 ± 0.00544 | 0.0573 ± 0.13905 |
| Month 12 after study treatment start (pre-randomization) | 0.0044 ± 0.00611 | 0.0037 ± 0.00440 | 0.0772 ± 0.56398 |
| Month 15 after study treatment start (pre-randomization) | 0.0035 ± 0.00591 | 0.0034 ± 0.00389 | 0.0669 ± 0.37209 |
| Month 18 after study treatment start (pre-randomization) | 0.0029 ± 0.00354 | 0.0034 ± 0.00409 | 0.0462 ± 0.12284 |
| Month 21 after study treatment start (pre-randomization) | 0.0028 ± 0.00319 | 0.0031 ± 0.00288 | 0.0390 ± 0.08271 |
| Month 24 after study treatment start (pre-randomization) | 0.0027 ± 0.00424 | 0.0029 ± 0.00319 | 0.0325 ± 0.05140 |
| Month 27 after study treatment start (post-randomization) | — | 0.0089 ± 0.06119 | — |
| Month 30 after study treatment start (post-randomization) | — | 0.0111 ± 0.08672 | — |
| Month 33 after study treatment start (post-randomization) | — | 0.0025 ± 0.00439 | — |
| Month 36 after study treatment start (post-randomization) | — | 0.0025 ± 0.00338 | — |
BCR-ABL/control gene (ABL) transcript ratio by international scale (IS) (expressed as a percentage) during the TFR phase. BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase.
| Percentage | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment Arm |
|---|---|---|
| Month 1 after entering the TFR phase | 0.0042 ± 0.00621 | 0.0074 ± 0.02130 |
| Month 2 after entering the TFR phase | 0.1162 ± 0.35606 | 0.2122 ± 0.99372 |
| Month 3 after entering the TFR phase | 1.3774 ± 9.71909 | 0.4754 ± 1.84649 |
| Month 4 after entering the TFR phase | 0.2667 ± 0.80336 | 0.2506 ± 0.91197 |
| Month 5 after entering the TFR phase | 0.1740 ± 0.76123 | 0.0801 ± 0.26739 |
| Month 6 after entering the TFR phase | 0.2219 ± 1.51808 | 0.1095 ± 0.66322 |
| Month 8 after entering the TFR phase | 0.0075 ± 0.01403 | 0.0042 ± 0.00742 |
| Month 10 after entering the TFR phase | 0.0062 ± 0.01295 | 0.0039 ± 0.00680 |
| Month 12 after entering the TFR phase | 0.0047 ± 0.00665 | 0.0027 ± 0.00357 |
| Month 15 after entering the TFR phase | 0.0030 ± 0.00317 | 0.0043 ± 0.00555 |
| Month 18 after entering the TFR phase | 0.0030 ± 0.00384 | 0.0027 ± 0.00330 |
| Month 21 after entering the TFR phase | 0.0036 ± 0.00484 | 0.0041 ± 0.00495 |
| Month 24 after entering the TFR phase | 0.0077 ± 0.02910 | 0.0047 ± 0.00691 |
| Month 27 after entering the TFR phase | 0.0024 ± 0.00246 | — |
| Month 30 after entering the TFR phase | 0.0023 ± 0.00281 | — |
| Month 33 after entering the TFR phase | 0.0079 ± 0.02376 | — |
| Month 36 after entering the TFR phase | 0.0041 ± 0.00767 | — |
BCR-ABL/control gene (ABL) transcript ratio by international scale (IS) (expressed as a percentage) during the nilotinib re-treatment phase. BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes.
| Percentage | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment Arm |
|---|---|---|
| Day 1 after entering the re-treatment phase | 2.8246 ± 2.39596 | 0.6301 ± 0.74388 |
| Week 6 after entering the re-treatment phase | 0.6276 ± 2.34231 | 0.3112 ± 0.60279 |
| Month 3 after entering the re-treatment phase | 0.0311 ± 0.07265 | 0.0131 ± 0.02359 |
| Month 6 after entering the re-treatment phase | 0.0095 ± 0.03296 | 0.0070 ± 0.01330 |
| Month 9 after entering the re-treatment phase | 0.0259 ± 0.17766 | 0.0065 ± 0.01099 |
| Month 12 after entering the re-treatment phase | 0.0088 ± 0.03190 | 0.0047 ± 0.00839 |
| Month 15 after entering the re-treatment phase | 0.0061 ± 0.01322 | 0.0045 ± 0.01176 |
| Month 18 after entering the re-treatment phase | 0.0105 ± 0.05205 | 0.0039 ± 0.00581 |
| Month 21 after entering the re-treatment phase | 0.0051 ± 0.01699 | 0.0031 ± 0.00342 |
| Month 24 after entering the re-treatment phase | 0.0038 ± 0.00756 | 0.0014 ± 0.00197 |
| Month 27 after entering the re-treatment phase | 0.0033 ± 0.00439 | — |
| Month 30 after entering the re-treatment phase | 0.0113 ± 0.04446 | — |
| Month 33 after entering the re-treatment phase | 0.0029 ± 0.00541 | — |
| Month 36 after entering the re-treatment phase | 0.0005 ± NA | — |
PFS is defined as the time from the date of start of the nilotinib TFR phase to the date of acelerated phase/blast crisis (AP/BC) or death, whichever came first. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotini 24-month treatment arm had a maximum of 36 months of TFR phase. Patients not known to have recurred or died on or before the cut-off date for PFS analysis were censored at the date of their last assessment (cytogenetic, hematology or extramedullary) for patients who were on study, and at the date of last contact for patients who were in follow-up.
| Months | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment Arm |
|---|---|---|
| Progression-free Survival (PFS) During the TFR Phase of the Study. | NA (NA to NA) | NA (NA to NA) |
TFS is defined as the time from the start of the TFR phase to the date of the earliest of the following: loss of MMR, confirmed loss of MR4.0,re-start of nilotinib treatment, progression to AP/BC, or death from any cause. Patients not known to have had any of the events on or before the cut-off date were censored at the earlier of the date of their last assessment for patients who were still on study and the date of last contact for patients who were in follow-up. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1%BCR-ABL. MR4.0 is defined as either detectable disease ≤0.01%BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)
| Months | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment Arm |
|---|---|---|
| Treatment -Free Survival (TFS) During the TFR Phase of the Study | 4.1 (3.7 to 5.5) | 4.2 (3.7 to 19.7) |
OS is defined as the time from start of the TFR phase to the time of death due to any cause. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotini 24-month treatment arm had a maximum of 36 months of TFR phase. For participants without any event on or before the cut-off date, survival time will be censored at the date of their last assessment for patients who are still on study, and at the date of last contact for patients who are in follow-up.
| Months | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment Arm |
|---|---|---|
| Overall Survival (OS) Rate During the TFR Phase of the Study. | NA (NA to NA) | NA (NA to NA) |
Deaths on-treatment were collected during the induction/consolidation phase (from the first dose of study drug to 30 days after study treatment discontinuation, assessed up to 24 months for Nilotinib 24-month treatment arm and Not randomized, and up to 36 months for Nilotinib 36-month treatment arm) and during the re-treatment phase (from the start date of the re-treatment phase to 30 days after study treatment discontinuation, assessed up to 36 months for Nilotinib 24-month treatment arm and up to 24 months for Nilotinib 36-month treatment arm). Total deaths were collected from first dose of study drug until end of study, up to maximum duration of 5 years
| Participants | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment | Not Randomized |
|---|---|---|---|
| On-treatment deaths | 1 | 1 | 3 |
| Total deaths | 1 | 3 | 10 |
Collected over - Induction/consolidation phase: From the first dose of study drug to 30 days after study treatment discontinuation, assessed up to 24 months for Nilotinib 24-month treatment arm and Not randomized, and up to 36 months for Nilotinib 36-month treatment arm. - Re-treatment phase: From the start date of the re-treatment phase to 30 days after study treatment discontinuation, assessed up to 36 months for Nilotinib 24-month treatment arm and up to 24 months for Nilotinib 36-month treatment arm. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nilotinib 24-month Treatment | 1/120 (0.8%) | 33/120 (27.5%) | 97/120 (80.8%) |
| Nilotinib 36-month Treatment | 1/118 (0.8%) | 27/118 (22.9%) | 104/118 (88.1%) |
| Not Randomized | 3/381 (0.8%) | 76/381 (19.9%) | 280/381 (73.5%) |
| Total | 5/619 (0.8%) | 136/619 (22%) | 481/619 (77.7%) |
| Event | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment | Not Randomized | Total |
|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 3/120 | 2/118 | 4/381 | 9/619 |
| CellulitisInfections and infestations | 1/120 | 2/118 | 0/381 | 3/619 |
| Acute coronary syndromeCardiac disorders | 2/120 | 0/118 | 1/381 | 3/619 |
| Myocardial infarctionCardiac disorders | 2/120 | 0/118 | 4/381 | 6/619 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/120 | 0/118 | 0/381 | 2/619 |
| DizzinessNervous system disorders | 2/120 | 0/118 | 0/381 | 2/619 |
| Angina pectorisCardiac disorders | 0/120 | 0/118 | 5/381 | 5/619 |
| Coronary artery diseaseCardiac disorders | 0/120 | 0/118 | 4/381 | 4/619 |
| Lymphadenopathy mediastinalBlood and lymphatic system disorders | 0/120 | 1/118 | 0/381 | 1/619 |
| Acute myocardial infarctionCardiac disorders | 0/120 | 1/118 | 2/381 | 3/619 |
| Event | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment | Not Randomized | Total |
|---|---|---|---|---|
| HypertensionVascular disorders | 20/120 | 25/118 | 27/381 | 72/619 |
| PruritusSkin and subcutaneous tissue disorders | 15/120 | 23/118 | 57/381 | 95/619 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 23/120 | 20/118 | 65/381 | 108/619 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 12/120 | 21/118 | 26/381 | 59/619 |
| Lipase increasedInvestigations | 21/120 | 10/118 | 34/381 | 65/619 |
| RashSkin and subcutaneous tissue disorders | 21/120 | 10/118 | 41/381 | 72/619 |
| ConstipationGastrointestinal disorders | 19/120 | 14/118 | 25/381 | 58/619 |
| Alanine aminotransferase increasedInvestigations | 10/120 | 18/118 | 27/381 | 55/619 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 17/120 | 18/118 | 27/381 | 62/619 |
| HeadacheNervous system disorders | 17/120 | 12/118 | 34/381 | 63/619 |
| Age, Categorical(Participants) | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment | Not Randomized | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 106 | 98 | 308 | 512 |
| >=65 years | 14 | 21 | 73 | 108 |
| Sex: Female, Male(Participants) | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment | Not Randomized | Total |
|---|---|---|---|---|
| Female | 48 | 49 | 129 | 226 |
| Male | 72 | 70 | 252 | 394 |
| Race/Ethnicity, Customized(Participants) | Nilotinib 24-month Treatment | Nilotinib 36-month Treatment | Not Randomized | Total |
|---|---|---|---|---|
| Caucasian | 114 | 112 | 355 | 581 |
| Black | 0 | 1 | 4 | 5 |
| Asian | 0 | 0 | 2 | 2 |
| Native American | 0 | 1 | 1 | 2 |
| North African descent | 1 | 0 | 1 | 2 |
| Unknown | 0 | 1 | 5 | 6 |
| Other | 5 | 4 | 13 | 22 |
Showing the first 100 of 208 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Apr 2013 to primary completion in Jul 2020, 86 months.
Results were first posted in Jul 2021, 1 year after primary completion.
Of 24 phase 3 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 79. This study's 86 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →